Navigation Links
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Date:3/16/2009

ntellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

                        Poniard Pharmaceuticals, Inc.
               Condensed Consolidated Statements of Operations
                    (In thousands, except per share data)
                                 (Unaudited)

                                      Three Months       Twelve Months
                                         Ended               Ended
                                      December 31,        December 31,
                                     ------------        -------------
                                      2008     2007      2008      2007
                                      ----     ----      ----      ----

    Revenues                            $-       $-        $-        $-
                                       ---      ---       ---       ---
    Operating expenses:
      Research and development      10,203    7,011    34,714  
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 ... Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray ... Hydrostatic Weighing) - Global Analysis & Forecast to 2019", ... was pegged at $911.1 Million 2014 and is estimated ... a CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... 2015  ResMed (NYSE: RMD ) ... agreement to acquire Curative Medical, a privately-held ... breathing medical devices and accessories. ... leadership in sleep and respiratory medicine, will ... suffering from sleep-disordered breathing and ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... 2011 Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused ... with respiratory diseases, today announced the appointment of Jaisim ... and Pravin Soni, PhD, as Senior Vice President and ... also announced that it drew down $17 million from ...
... Lilly and Company (NYSE: LLY ) announced ... Medicinal Products for Human Use (CHMP) has issued a ... injection) as continuation maintenance therapy in patients with advanced ... the CHMP are reviewed by the European Commission, which ...
Cached Medicine Technology:Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 2Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 3ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer 2ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer 3ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer 4ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer 5ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer 6ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer 7
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, Sigma ... the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. Key ... meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit of ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... communicate. Rally Insurance Group, Inc. has re-branded their social media profiles to better ... personal way for consumers to communicate, find information, share insights and opinions. The ...
(Date:7/31/2015)... Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... surgeons and cosmetic experts gathered to see if they could reach a consensus on ... including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... to prescription painkillers are more likely to succeed ... medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard ... the Archives of General Psychiatry. ... for Prescription Opioid Dependence," is the first large-scale ...
... A microsurgical procedure that has lost some ground ... role in the management of selected neurovascular disorders, according ... performs the procedure. "Though its indications are ... make all the difference for certain patients who have ...
... , MONDAY, Nov. 7 (HealthDay News) -- ... school athletes, a new study indicates. In neuromuscular ... progresses to focusing on muscles and motions used in ... and almost 1,500 female basketball and soccer players from ...
... by 2007 annual sales of the cards were at 85,000. America ... in the U.S. over the age of 80 is expected to ... how well they live. The new book, Aging Our Way ... of 30 eldersranging in age from 85 to 102living at home ...
... Go Fish with 3,000 cards. Scientists at Rochester Institute ... game with higher stakes. Instead of cards, they are matching ... body. Their research could lead to drugs that target proteins ... diseases. The three-year study is funded by a $417,000 ...
... who believe a rule or restriction is absolute are more likely ... wiggle room, according to a new study. The findings may ... Arab Spring uprisings, according to the authors of the study to ... Science . In the study, participants read articles that ...
Cached Medicine News:Health News:Suboxone is most effective in treating painkiller addiction 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 3Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:What can we learn from America's fastest growing and least understood age group? 2Health News:Opening the data bank -- scientists try to match new protein structures 2Health News:People Seem More Likely to Follow Rules They Can't Beat 2
... Portex® Thermovent® T helps provide protection to the ... small and extremely lightweight making it ideal for ... a high rate of heat and moisture recovery, ... ,All HMEs and filters have ISO standard ...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
Medicine Products: